Twinvir ™ — combined antiviral agent.
One Buy Twinvir ™ tablet contains Ladipasvir 90 mg and Sophosbuvir 400 mg.
The combination of Ledipasvir and Sofosbuvir is used for the treatment of hepatitis C of genotype 1, 4, 5 and 6 in adults.
28 tablets, film-coated.
Dosage and Administration
Recommended dosage: one tablet (Ladipasvir 90 mg and Sofosbuvir 400 mg) is taken orally once a day. Recommended duration of treatment for patients without experience of negative response to therapy: 12 weeks. With experience of a negative response to therapy (without cirrhosis of the liver): 24 weeks. With experience of a negative response to therapy (with cirrhosis of the liver): 24 weeks.
Joint use of the drug with amiodarone can lead to bradycardia. P-gp inductors (rifampicin, rifabutin, St. John’s wort, carbmazepine, phenobarbital and phenytoin) lower the concentration of Ladipasvir and Sofosbuvir in the blood, which adversely affects the effectiveness of treatment.
Pregnancy and Lactation
There is no data on the effect of the drug on fetal development and lactation. During pregnancy and breastfeeding, the drug can be prescribed only by the therapist.
The safety and efficacy of the combination of Ledipasvir and Sofosbuvir in patients under 18 years of age have not been studied.
Twinvir ™ is available in the form of tablets for oral administration. The composition includes two active components: Ladipasvir, which is an inhibitor of the viral protein, and also Sofosbuvir, an inhibitor of the RNA polymerase.
Bradycardia can occur in patients taking amiodarone, especially those who simultaneously use amiodarone with other drugs that slow the heart rate. The joint administration of amiodarone with the combination of Ledipasvir and Sofosbuvirais not recommended. Cardiac monitoring is recommended in patients without alternative treatment options. The dosage for patients with severe renal failure or renal insufficiency of the final stage is calculated individually by the attending physician. The use of Twinvir ™ with other drugs containing Sofosbuvir is not recommended.